Asset Details
Do you wish to reserve the book?
Design and biological evaluation of mesalamine–NSAID hybrids targeting the NLRP3 inflammasome: a multi-target strategy for ulcerative colitis therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Design and biological evaluation of mesalamine–NSAID hybrids targeting the NLRP3 inflammasome: a multi-target strategy for ulcerative colitis therapy
Do you wish to request the book?
Design and biological evaluation of mesalamine–NSAID hybrids targeting the NLRP3 inflammasome: a multi-target strategy for ulcerative colitis therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Design and biological evaluation of mesalamine–NSAID hybrids targeting the NLRP3 inflammasome: a multi-target strategy for ulcerative colitis therapy
2025
Overview
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by epithelial damage, excessive cytokine release, and dysregulated inflammasome activation. Herein, we report the design, synthesis, and multi-targeted biological evaluation of three novel mesalamine–NSAID hybrid derivatives (D1, D3, and D4) as potential therapeutic agents for UC. Structural hybridization was employed to enhance colonic targeting, suppress NLRP3 inflammasome signaling, and reduce systemic toxicity. All compounds were characterized and screened for anti-inflammatory efficacy via qRT-PCR analysis of key inflammasome-related genes (NLRP3, IL1B, IL-18, Caspase-1) in LPS-activated macrophages. Compound D3 exhibited the most potent downregulation profile, supported by molecular docking studies showing favorable interactions with NLRP3 and caspase-1. Antioxidant activity was evaluated using the DPPH assay, with D3 demonstrating the lowest IC
50
(19.20 µg/mL). Antimicrobial and brine shrimp lethality assays confirmed the moderate cytotoxicity profiles and pathogen-inhibitory potential of all compounds. Collectively, these results highlight D3 as a dual-action anti-inflammatory and antioxidant agent capable of modulating key immune and redox pathways implicated in UC pathogenesis. The study supports mesalamine–NSAID hybridization as a promising strategy for developing next-generation UC therapeutics with improved efficacy and safety profiles.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/250
/ 631/45
/ 692/699
/ Animals
/ Anti-Inflammatory Agents, Non-Steroidal - chemistry
/ Anti-Inflammatory Agents, Non-Steroidal - pharmacology
/ Colitis, Ulcerative - drug therapy
/ Colitis, Ulcerative - metabolism
/ Colon
/ Design
/ Humanities and Social Sciences
/ Humans
/ Hybrids
/ Inflammasomes - drug effects
/ Mice
/ Molecular Docking Simulation
/ Nitrogen
/ NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors
/ NLR Family, Pyrin Domain-Containing 3 Protein - metabolism
/ Nonsteroidal anti-inflammatory drugs
/ Science
/ Toxicity
